Background: Proposals for population screening for genetic diseases require careful scrutiny by decision makers because of the potential for harms and the need to demonstrate benefits commensurate with the opportunity cost of resources expended. Methods: We review current evidence-based processes used in the United States, the United Kingdom, and the Netherlands to assess genetic screening programs, including newborn screening programs, carrier screening, and organized cascade testing of relatives of patients with genetic syndromes. In particular, we address critical evidentiary, economic, and ethical issues that arise in the appraisal of screening tests offered to the population. Specific case studies include newborn screening for congenital adrenal hyperplasia and cystic fibrosis and adult screening for hereditary hemochromatosis. Results: Organizations and countries often reach different conclusions about the suitability of screening tests for implementation on a population basis. Deciding when and how to introduce pilot screening programs is challenging. In certain cases, e.g., hereditary hemochromatosis, a consensus does not support general screening although cascade screening may be cost-effective. Conclusion: Genetic screening policies have often been determined by technological capability, advocacy, and medical opinion rather than through a rigorous evidence-based review process. Decision making should take into account principles of ethics and opportunity costs.

Keywords:
Clinical utility, Cost-effectiveness, ELSI, Genetic testing, Newborn screening
1.
Andermann A, Blancquaert I, Beauchamp S, Déry V: Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317–319.
2.
Health Council of the Netherlands: Screening: between hope and hype. Publication No. 2008/05E. The Hague, Health Council of the Netherlands, 2008.
3.
Khoury MJ, McCabe L, McCabe ER: Population screening in the age of genomic medicine. New Engl J Med 2003;348:50–58.
4.
Nuffield Council on Bioethics: Genetic screening: a supplement to the 1993 report by the Nuffield Council on Bioethics, 2006. Available at www.nuffieldbioethics.org.
5.
Potter BK, Avard D, Entwistle V, Kennedy C, Chakraborty P, McGuire M, Wilson BJ: Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report. Public Health Genomics 2009;12:4–10.
6.
Homsma SJ, Huijgen R, Middeldorp S, Sijbrands EJ, Kastelein JJ: Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. Eur J Hum Genet 2008;16:14–17.
7.
National Institute for Health and Clinical Excellence: clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia, 2008 (Clinical Guideline 71.). Available at www.nice.org.uk/CG71.
8.
Loeber JG: Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis 2007;30:430–438.
9.
Therrell BL, Adams J: Newborn screening in North America. J Inherit Metab Dis 2007;30:447–465.
10.
Radhakrishnan M, van Gool K, Hall J, Delatycki M, Massie J: Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 2008;85:133–147.
11.
De Wert GMWR, Dondorp WJ: Prenatal medicine: ethical issues, in van Vugt MG, Shulman LP (eds): Prenatal Medicine. New York, Taylor & Francis Group, 2006, pp 575–604.
12.
Morris JK, Law MR, Wald NJ: Is cascade testing a sensible method of screening a population for autosomal recessive disorders? Am J Med Genet A 2004;128A:271–275.
13.
Simopoulos AP, Childs B: Committee for the Study of Inborn Errors of Metabolism, Division of Medical Sciences, Assembly of Life Sciences, National Research Council: Genetic Screening: Programs, Principles, and Research. Washington, DC, National Academy of Sciences, 1975.
14.
Simopoulos AP: Genetic screening: programs, principles, and research – thirty years later. Reviewing the recommendations of the committee for the study of inborn errors of metabolism (SIEM). Public Health Genomics 2009;12:105–111.
15.
National Screening Committee: Chapter 6. The NSC Handbook of Population Screening Programmes – First Edition, in First Report of the National Screening Committee. Health Departments of the United Kingdom, 1998.
16.
U.S. Secretary’s Advisory Committee on Genetics, Health, and Society: U.S. System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of HHS. Washington, DC, Department of Health and Human Services, 2008.
17.
Sassi F, Archard L, Le Grand J: Equity and economic evaluation of healthcare. Health Technol Assess 2001;5:1–138.
18.
Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S: Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004;8:1–121.
19.
Grosse SD, Dezateux C: Newborn screening for inherited metabolic disease. Lancet 2007;369:5–6.
20.
Bodamer OA, Hoffmann GF, Lindner M: Expanded newborn screening in Europe 2007. J Inherit Metab Dis 2007;30:439–444.
21.
Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L: The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9:665–674.
22.
U.S. Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355–361.
23.
Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO; EGAPP Working Group: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP working group. Genet Med 2009;11:3–14.
24.
Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN: EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:1–22.
25.
American Academy of Pediatrics: Serving the family from birth to the medical home. A report from the Newborn Screening Task Force convened in Washington, DC, May 10–11, 1999. Pediatrics 2000;106:383–427.
26.
Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS, CDC: Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004;53:1–36.
27.
American College of Medical Genetics Newborn Screening Expert Group: Newborn screening: toward a uniform screening panel and system–executive summary. Pediatrics 2006;117:S296–S307.
28.
Botkin JR, Clayton EW, Fost NC, Burke W, Murray TH, Baily MA, Wilfond B, Berg A, Ross LF: Newborn screening technology: proceed with caution. Pediatrics 2006;117:1793–1799.
29.
Moyer VA, Calonge N, Teutsch SM, Botkin JR; United States Preventive Services Task Force: Expanding newborn screening: process, policy, and priorities. Hastings Cent Rep 2008;38:32–39.
30.
Baily MA, Murray TH: Ethics, evidence, and cost in newborn screening. Hastings Cent Rep 2008;38:23–31.
31.
President’s Council on Bioethics: The Changing Moral Focus of Newborn Screening: An Ethical Analysis by the President’s Council on Bioethics. Washington, DC, 2008. Available at www.bioethics.gov.
32.
March of Dimes: States expand newborn screening for life-threatening disorders. Press release. March of Dimes, White Plains, NY, February 18, 2009. Available at http://www.marchofdimes.com/aboutus/22684_51920.asp.
33.
Green NS, Rinaldo P, Brower A, Boyle C, Dougherty D, Lloyd-Puryear M, Mann MY, Howell RR; Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children: Committee Report: advancing the current recommended panel of conditions for newborn screening. Genet Med 2007;9:792–796.
34.
Health Council of the Netherlands: Annual report on screening for disease 2007. Medical self-test kits. Publication No. 2007/26E. The Hague, Health Council of the Netherlands, 2007.
35.
Health Council of the Netherlands: Neonatal Screening. Publication No. 2005/11E. The Hague, Health Council of the Netherlands, 2005.
36.
Grosse SD, Van Vliet G: How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res 2007;67:284–291.
37.
Strnadova KA, Votava F, Lebl J, Mühl A, Item C, Bodamer OA, Torresani T, Bouska I, Waldhauser F, Sperl W: Prevalence of congenital adrenal hyperplasia among sudden infant death in the Czech Republic and Austria. Eur J Pediatr 2007;166:1–4.
38.
Grosse SD, Van Vliet G: Outcomes in CAH: Need for evidence-based estimates. Horm Res 2007;68:203.
39.
Grosse SD, Rosenfeld M, Devine OJ, Lai HJ, Farrell PM: Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr 2006;149:362–366.
40.
Adams PC, Barton JC: Haemochromatosis. Lancet 2007;370:1855–1860.
41.
Watkins S, Thorburn D, Joshi N, Neilson M, Joyce T, Spooner R, Cooke A, Mills PR, Morris AJ, Stanley AJ: The biochemical and clinical penetrance of individuals diagnosed with genetic haemochromatosis by predictive genetic testing. Eur J Gastroenterol Hepatol 2008;20:379–383.
42.
Adams PC, Passmore L, Chakrabarti S, Reboussin DM, Acton RT, Barton JC, McLaren GD, Eckfeldt JH, Dawkins FW, Gordeuk VR, Harris EL, Leiendecker-Foster C, Gossman E, Sholinsky P: Hemochromatosis and iron overload screening study research investigators: liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006;4:918–923.
43.
Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM: Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221–230.
44.
U.S. Preventive Services Task Force: Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006;145:204–208.
45.
Phatak PD, Bonkovsky HL, Kowdley KV: Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008;149:270–272.
46.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL: Methods for the Economic Evaluation of Health Care Programs, ed 3. Oxford, Oxford University Press, 2005.
47.
Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD: Economic analyses of human genetics services: a systematic review. Genet Med 2005;7:519–523.
48.
Jarrett J, Mugford M: Genetic health technology and economic evaluation: a critical review. Appl Health Econ Health Policy 2006;5:27–35.
49.
Rogowski W: Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care 2006;22:327–337.
50.
Grosse SD, Wordsworth S, Payne K: Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 2008;10:648–654.
51.
Bridges JFP: Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy 2003;2:213–224.
52.
Cohen JT, Neumann PJ, Weinstein MC: Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 2008;358:661–663.
53.
Devlin N, Parkin D: Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437–452.
54.
Grosse SD: Assessing cost-effectiveness in healthcare: history of the USD 50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8:165–178.
55.
Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL: World Health Organization: Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: WHO, 2003. Available at http://www.who.int/choice/publications/p_2003_generalised_cea.pdf.
56.
Council for Public Health and Health Care (RVZ): Sensible and sustainable care [report in Dutch]. Publication No. 2006/06. The Hague, RVZ, 2006.
57.
Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI: Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 2006;31:52–61.
58.
Grosse SD, Teutsch SM, Haddix AC: Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health 2007;28:365–391.
59.
Grosse SD: Cost effectiveness as a criterion for newborn screening policy decisions: a critical review, in Baily MA, Murray TH (eds): Ethics and Newborn Genetic Screening: New Technologies, New Challenges. Baltimore, Johns Hopkins University Press, 2009, pp 58–88.
60.
Grosse SD, Olney RS, Baily MA: The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK. Appl Health Econ Health Policy 2005;4:239–247.
61.
Carroll AE, Downs SM: Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics 2006;117:287–295.
62.
Norman R, Haas M, Wilcken B: International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions. Health Policy 2009;89:252–260.
63.
Yoo BK, Grosse SD: The cost effectiveness of screening newborns for congenital adrenal hyperplasia. Public Health Genomics 2009;12:67–72.
64.
van den Akker-van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse JE: Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 2006;118:896–905.
65.
Sims EJ, Mugford M, Clark A, Aitken D, McCormick J, Mehta G, Mehta A; UK Cystic Fibrosis Database Steering Committee: Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007;369:1187–1195.
66.
Rogowski W: The cost-effectiveness of DNA-based screening for hereditary hemochromatosis in Germany: a re-modeling study. Med Decis Making 2009;29:224–238.
67.
Kemper AR, Fant KE, Clark SJ: Informing parents about newborn screening. Public Health Nurs 2005;22:332–338.
68.
Ross LF: Ethical and policy issues in pediatric genetics. Am J Med Genet C Semin Med Genet 2008;148C:1–7.
69.
Clayton EW: Talking with parents before newborn screening. J Pediatr 2005;147:S26–S29.
70.
Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG: Assessing Genetic Risks: Implications for Health and Social Policy. Washington, DC, National Academies Press, 1994.
71.
Nelson RM, Botkjin JR, Kodish ED, Levetown M, Truman JT, Wilfond BS, Harrison CE, Kazura A, Krug E 3rd, Schwartz PA, Donovan GK, Fallat M, Porter IH, Steinberg D; Committee on Bioethics: Ethical issues with genetic testing in pediatrics. Pediatrics 2001;107:1451–1455.
72.
Detmar S, Hosli E, Dijkstra N, Nijsingh N, Rijnders M, Verweij M: Information and informed consent for neonatal screening: opinions and preferences of parents. Birth 2007;34:238–244.
73.
Dhondt JL: Implementation of informed consent for a cystic fibrosis newborn screening program in France: low refusal rates for optional testing. J Pediatr 2005;147:S106–S108.
74.
Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS: From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics 2006;117:923–929.
75.
Bailey DB Jr, Skinner D, Davis AM, Whitmarsh I, Powell C: Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues. Pediatrics 2008;121:e693–e704.
76.
Atkinson K, Zuckerman B, Sharfstein JM, Levin D, Blatt RJ, Koh HK: A public health response to emerging technology: expansion of the Massachusetts newborn screening program. Public Health Rep 2001;116:122–131.
77.
Tarini BA, Burke W, Scott CR, Wilfond BS: Waiving informed consent in newborn screening research: balancing social value and respect. Am J Med Genet C Semin Med Genet 2008;148C:23–30.
78.
Tarini BA, Christakis DA, Welch HG: State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics 2006;118:448–456.
79.
Ross LF: Newborn screening for cystic fibrosis: a lesson in public health disparities. J Pediatr 2008;153:308–313.
80.
Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, Castellani C; ECFS CF Neonatal Screening Working Group: A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 2007;6:57–65.
81.
Comeau AM, Larson C, Eaton RB: Integration of new genetic diseases into statewide newborn screening: New England experience. Am J Med Genet C Semin Med Genet 2004;125C:35–41.
82.
Comeau AM, Accurso FJ, White TB, Campbell PW 3rd, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O’Sullivan BP; Cystic Fibrosis Foundation: Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007;119:e495–e518.
83.
Giusti R, Badgwell A, Iglesias AD; New York State Cystic Fibrosis Newborn Screening Consortium: New York State cystic fibrosis consortium: the first 2.5 years of experience with cystic fibrosis newborn screening in an ethnically diverse population. Pediatrics 2007;119:e460–e467.
84.
Health Council of the Netherlands: Preconception care: a good beginning. Publication No. 2007/19E. The Hague, Health Council of the Netherlands, 2007.
85.
Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP: Three-month follow-up of Western and non- Western participants in a study on preconceptional ancestry-based carrier couple screening for cystic fibrosis and hemoglobinopathies in the Netherlands. Genet Med 2008;10:820–830.
86.
Dyson SM: Ethnicity and Screening for Sickle cell/Thalassemia: Lessons for Practice from the Voices of Experience. Edinburgh, Elsevier Churchill Livingstone, 2005.
87.
Lakeman P, Henneman L, Bezemer PD, Cornel MC, ten Kate LP: Developing and optimizing a decisional instrument using self-reported ancestry for carrier screening in a multi-ethnic society. Genet Med 2006;8:502–509.
88.
Bailey DB Jr, Skinner D, Warren SF: Newborn screening for developmental disabilities: reframing presumptive benefit. Am J Public Health 2005;95:1889–1893.
89.
Pass KA, Lane PA, Fernhoff PM, Hinton CF, Panny SR, Parks JS, Pelias MZ, Rhead WJ, Ross SI, Wethers DL, Elsas LJ 2nd: US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr 2000;137:S1–S46.
90.
Farrell M, Certain L, Farrell P: Genetic counseling and risk communication services of newborn screening programs. Arch Pediatr Adolesc Med 2001;155:120–126.
91.
Kladny B, Gettig EA, Krishnamurti L: Systematic follow-up and case management of the abnormal newborn screen can improve acceptance of genetic counseling for sickle cell or other hemoglobinopathy trait. Genet Med 2005;7:139–142.
92.
Kavanagh PL, Wang CJ, Therrell BL, Sprinz PG, Bauchner H: Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states. Am J Med Genet C Semin Med Genet 2008;148C:15–22.
93.
Oliver S, Dezateux C, Kavanagh J, Lempert T, Stewart R: Disclosing to parents newborn carrier status identified by routine blood spot screening. Cochrane Database Syst Rev 2004;18:CD003859.
94.
La Pean A, Farrell MH: Initially misleading communication of carrier results after newborn genetic screening. Pediatrics 2005;116:1499–1505.
95.
Lewis S, Curnow L, Ross M, Massie J: Parental attitudes to the identification of their infants as carriers of cystic fibrosis by newborn screening. J Paediatr Child Health 2006;42:533–537.
96.
Borry P, Nys H, Dierickx K: Carrier testing in minors: conflicting views. Nat Rev Genet 2007;8:828.
97.
Lakeman P, Gille JJ, Dankert-Roelse JE, Heijerman HG, Munck A, Iron A, Grasemann H, Schuster A, Cornel MC, Ten Kate LP: CFTR mutations in Turkish and North African cystic fibrosis patients in Europe: implications for screening. Genet Test 2008;12:25–35.
98.
Kenny N, Joffres C: An ethical analysis of international health priority-setting. Health Care Anal 2008;16:145–160.
99.
Meltzer MI: Health economics and prioritising health care. Lancet 2008;372:612–613.
100.
Burton H, Adams M, Bunton R, Schröder-Bäck P: Developing stakeholder involvement for introducing public health genomics into public policy. Public Health Genomics 2009;12:11–19.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.